HMN Financial Inc
Change company Symbol lookup
Select an option...
HMNF HMN Financial Inc
BAM Brookfield Asset Management Inc
XOM Exxon Mobil Corp
NEWR New Relic Inc
T AT&T Inc
AICAF Air China Ltd
MMM 3M Co
JNJ Johnson & Johnson
TIP iShares TIPS Bond ETF
OCUL Ocular Therapeutix Inc
Go

Financials : Thrifts & Mortgage Finance | Small Cap Value
Company profile

HMN Financial, Inc. (HMN) is a stock savings bank holding company that owns Home Federal Savings Bank (the Bank). The Bank operates retail banking and loan production facilities in Minnesota, Iowa and Wisconsin. The Bank has two subsidiaries, Osterud Insurance Agency, Inc., which offers financial planning products and services, and HFSB Property Holdings, LLC, which acts as an intermediary for the Bank in holding and operating certain foreclosed properties. HMN's business involves attracting deposits from the general public and businesses and using such deposits to originate or purchase one- to four-family residential, commercial real estate and multi-family mortgage loans, among others. HMN invests in mortgage-backed and related securities, the United States government agency obligations and other permissible investments. HMN serves the southern Minnesota counties of Dodge, Fillmore, Freeborn, Houston, Mower, Olmsted and Winona, and portions of Steele, Goodhue and Wabasha.

Closing Price
$13.40
Day's Change
0.10 (0.75%)
Bid
--
Ask
--
B/A Size
--
Day's High
13.40
Day's Low
13.40
Volume
(Heavy Day)
Volume:
2,276

10-day average volume:
2,733
2,276

Invitation to MorphoSys' Second Quarter and First Half 2020 Results Conference Call on August 6, 2020

4:21 pm ET July 30, 2020 (Accesswire) Print

PLANEGG & MUNICH, GERMANY / ACCESSWIRE / July 30, 2020 / Invitation to MorphoSys' Second Quarter and First Half 2020 Results Conference Call on August 6, 2020

MorphoSys AG (FSE:MOR)(Prime Standard Segment, MDAX & TecDAX) (NASDAQ:MOR) will publish its results for the second quarter and first half of 2020 on August 5, 2020 at 10:00pm CEST (9:00pm BST; 4:00pm EDT).

MorphoSys' Management team will host a conference call and webcast on August 6, 2020 at 2:00pm CEST (1:00pm BST; 8:00am EDT) to present the second quarter and first half financial results 2020 and the further outlook for 2020.

Date of the conference call:Thursday, August 6, 2020
Time:2:00pm CEST (1:00pm BST, 8:00am EDT)
Dial-in numbers:
Germany:+49 69 201 744 220
United Kingdom:+44 203 009 2470
USA: +1 877 423 0830
(all numbers reachable from any geography)
Participant PIN:43014391#



Please dial in 10 minutes before the beginning of the conference.

A live webcast and slides will be made available at www.morphosys.com.

Approximately two hours after the call, a slide-synchronized audio replay of the conference and a transcript of the prepared remarks will be available on www.morphosys.com.

About MorphoSys

MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, 27 of which are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys' antibody technology to receive regulatory approval. MorphoSys most advanced proprietary product candidate, tafasitamab (MOR208), is in late-stage clinical development for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has ~500 employees. More information at www.morphosys.com



HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R), LanthioPep(R) and ENFORCER(R) are trademarks of the MorphoSys Group. Tremfya(R) is a trademark of Janssen Biotech, Inc. XmAb(R) is a trademark of Xencor, Inc.

MorphoSys forward looking statements

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys' expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

For more information, please contact:

MorphoSys

Investor Contacts:



Dr. Anja Pomrehn

Senior Vice President

Tel: +49 (0) 89 / 899 27-26972

Anja.Pomrehn@morphosys.com

Dr. Julia Neugebauer

Director

Tel: +49 (0) 89 / 899 27-179

Julia.Neugebauer@morphosys.com

Media Contacts:

Jeanette Bressi

Director, US Communications

Tel: +1 617-404-7816

media@morphosys.com



Dr. Anca Ammon

Associate Director

Tel: +49 (0) 89 / 899 27-26738

media@morphosys.com

SOURCE: MorphoSys AG via EQS Newswire





View source version on accesswire.com:

https://www.accesswire.com/599696/Invitation-to-MorphoSys-Second-Quarter-and-First-Half-2020-Results-Conference-Call-on-August-6-2020



comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.